| Laura B Thomas-cousar, PT | |
|
13130 Cane Lake Ct, Sugar Land, TX 77498-7418 | |
| (713) 334-1818 | |
| Not Available |
| Full Name | Laura B Thomas-cousar |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 35 Years |
| Location | 13130 Cane Lake Ct, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013132935 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1056034 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pt Care Specialists, Llc | 1153720685 | 10 |
News Archive
An international team of scientists have discovered a new class of compounds that inhibit bacterial DNA gyrase.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
A controversial debt panel's advice was initially thought to be heading nowhere fast, but a surprisingly broad consensus that action must be taken to avoid a debt crisis has kept negotiators at the table and given the recommendations unexpected buoyancy, The Washington Post reports.
Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life.
Adolescents and young adults experiencing relative declines in cognitive performance have an increased risk for later psychosis, with a decline in verbal ability between 13 and 18 years of age a strong predictor, conclude researchers.
› Verified 8 days ago
| Provider Name | Physical Therapy Care Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1952379760 PECOS PAC ID: 5890720544 Enrollment ID: O20050930000313 |
News Archive
An international team of scientists have discovered a new class of compounds that inhibit bacterial DNA gyrase.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
A controversial debt panel's advice was initially thought to be heading nowhere fast, but a surprisingly broad consensus that action must be taken to avoid a debt crisis has kept negotiators at the table and given the recommendations unexpected buoyancy, The Washington Post reports.
Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life.
Adolescents and young adults experiencing relative declines in cognitive performance have an increased risk for later psychosis, with a decline in verbal ability between 13 and 18 years of age a strong predictor, conclude researchers.
› Verified 8 days ago
| Provider Name | Pt Care Specialists, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1396319836 PECOS PAC ID: 1153720685 Enrollment ID: O20210602003274 |
News Archive
An international team of scientists have discovered a new class of compounds that inhibit bacterial DNA gyrase.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
A controversial debt panel's advice was initially thought to be heading nowhere fast, but a surprisingly broad consensus that action must be taken to avoid a debt crisis has kept negotiators at the table and given the recommendations unexpected buoyancy, The Washington Post reports.
Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life.
Adolescents and young adults experiencing relative declines in cognitive performance have an increased risk for later psychosis, with a decline in verbal ability between 13 and 18 years of age a strong predictor, conclude researchers.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura B Thomas-cousar, PT 534 Sunny River Ln, Richmond, TX 77406-2176 Ph: (281) 232-3954 | Laura B Thomas-cousar, PT 13130 Cane Lake Ct, Sugar Land, TX 77498-7418 Ph: (713) 334-1818 |
News Archive
An international team of scientists have discovered a new class of compounds that inhibit bacterial DNA gyrase.
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
A controversial debt panel's advice was initially thought to be heading nowhere fast, but a surprisingly broad consensus that action must be taken to avoid a debt crisis has kept negotiators at the table and given the recommendations unexpected buoyancy, The Washington Post reports.
Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life.
Adolescents and young adults experiencing relative declines in cognitive performance have an increased risk for later psychosis, with a decline in verbal ability between 13 and 18 years of age a strong predictor, conclude researchers.
› Verified 8 days ago
Rehab Experts Katy Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1110 Lakeview Dr, Sugar Land, TX 77478 Phone: 832-348-7298 | |
Sienna Kahlden, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 17520 W Grand Pkwy S Ste 100, Sugar Land, TX 77479 Phone: 281-725-5895 | |
Ms. Soraya C Rodriguez, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 15400 Southwest Fwy, Suite 100, Sugar Land, TX 77478 Phone: 281-565-8800 Fax: 281-565-8808 | |
Robert Horry Center For Sports And Physical Rehabilitation, Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 15591 Creek Bend Dr, Sugar Land, TX 77478 Phone: 281-277-0751 Fax: 281-277-0761 | |
Ms. Megan Leigh Ellis, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 20403 University Blvd Ste 100, Sugar Land, TX 77478 Phone: 281-325-0188 Fax: 281-325-0189 | |
Erich Hunter Gaulke, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4945 Sweetwater Blvd, Sugar Land, TX 77479 Phone: 281-277-1330 |